Amanda Nanasy, OD, discussed how sports can open the door to eye care for underserved athletes and what goes into her performance vision evaluations.
|Articles|December 3, 2015
How ODs can do better with dry eye
Scott Schachter, OD, says there have been a lot of advancements in technology that helps diagnose and treat dry eye, but he says there's still more optometrists can do.
Advertisement
Scott Schachter, OD, says there have been a lot of advancements in technology that helps diagnose and treat
Advertisement
Related to this article
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host Diana Canto-Sims, OD.
Amanda Nanasy, OD, described how her own concussion shaped her approach to athletes and why she ties every vision evaluation back to the demands of their sport.
Zachary Keaney, CPOA, discusses the lens care steps patients skip most often and why early diagnosis of lens-related keratitis is critical.
This week's top stories include breaking FDA approvals, insights on AI-assisted front desk management, and more.
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA designates OCT-980 as orphan drug for retinitis pigmentosa
2
Tying eye health to performance encourages athletes to seek care
3
Why performance vision evaluations matter for athletes
4
The Independent Advantage S02 E08: The makings of a great patient experience
5